Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Latest filing published 08 Jun 2023 for Marker Therapeutics, Inc., €210k. Read the official filing
Filing timeline
BuySaleNorman David Eansor
Insider track record
Disclosed buys
1
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Norman David Eansor: trading record in brief
Norman David Eansor, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in BIO-TECHNE Corp and Marker Therapeutics, Inc. Over a trading history stretching from 16 March 2021 to 12 November 2021, the count stands at 5 filings.
The open-market side counts 1 purchase for €210k alongside 1 sale for €655k. Netting one side against the other leaves €446k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant and 2 option exercises. 2023 to date brings 1 purchase and no sales.
The latest filing, published on 8 June 2023, reports an open-market purchase of €210k in Marker Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Norman David Eansor
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
14,285 shares@ US$17.50100.0% of flowCommon StockSEC:0001209191-23-035617:0
Canonical exit: 14 Jun 2021 (T+90)
27,159 shares@ US$125.0581.9% of flowCommon StockSEC:0000914190-21-000405:0
1,538 shares@ US$503.073918.1% of flowCommon StockSEC:0000914190-21-000322:0
2,537 shares0Common StockSEC:0000914190-21-000213:0
12,658 shares0Common StockSEC:0001209191-21-039631:0
5 of 5 declarations
